文献速递甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

美国 nationwide 调查:2011 年 NRC 患者出院政策实施后甲状腺癌 131I 治疗实践变化

Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer.
PubMed 文献 · J Nucl Med · 2019-08-26

该调查通过电子邮件向 ThyCa 约 25,000 名成员发放问卷,纳入 1,111 例成人患者最近一次 2011–2018 年 131I 治疗数据,并与 1997–2009 年治疗数据比较。结果显示,2011 年后门诊治疗比例更高、出院更快,患者能更多讨论并个体化辐射安全指导,但仍有 2% 患者回忆未接受辐射安全指导。

要点

  • 2011 年后 87% 患者以门诊方式接受 131I 治疗,高于 2009 年前的 66%(P < 0.001)。
  • 2011 年后 67% 患者能讨论并个体化辐射安全指导,高于 2009 年前的 29%(P < 0.001)。
  • 2011 年后 2% 患者回忆从未接受辐射安全指导。

核心结论

  • 调查提示,自 NRC 2011-01 患者出院政策发布以来,门诊患者出院时部分辐射安全实践有所改善,患者在出行和住宿方面的依从性也有所改善。

研究设计与样本

  • 通过电子邮件向 ThyCa 约 25,000 名成员发放调查问卷,2018 年 3–8 月在线开放,纳入成人患者 2011–2018 年最近一次 131I 治疗数据,并与既往类似调查的 1997–2009 年治疗数据比较。

主要发现

  • 2,136 份回复中 1,111 份符合纳入标准,2011 年后与 2009 年前约 98% 患者均获得口头或书面辐射安全指导。
  • 2011 年后由核医学医师提供指导的比例为 43%,低于 2009 年前的 54%(P < 0.001)。
  • 2011 年后 67% 患者能讨论并个体化辐射安全指导,高于 2009 年前的 29%(P < 0.001)。
  • 2011 年后 87% 患者接受门诊治疗,高于 2009 年前的 66%(P < 0.001);门诊患者在 131I 治疗后 30 分钟内出院的比例为 78%,高于 2009 年前的 72%(P = 0.002)。
  • 2011 年后与 2009 年前均有 0.6% 患者在治疗后约 1 米内与至少 2 名同车者同行超过 2 小时;治疗后立即住在非私人住所的比例分别为 4% 和 5%(P = 0.28)。

关键数值与推荐

  • 2011 年后 2% 患者回忆从未接受辐射安全指导。
  • 27 例在 30 分钟内出院的非私人住所门诊患者中,2 例接受 5.55–11.1 GBq(150–299 mCi)131I 治疗。

临床怎么用

  • 核医学医师应继续向 131I 治疗患者提供辐射安全指导,并争取在出院前与患者讨论、个体化指导内容。
  • 对门诊患者出院时应关注其出行和住宿安排,尤其需注意同车同行和非私人住所等场景。

局限性

  • 研究为患者回忆性问卷调查,可能存在回忆偏倚。
  • 调查通过 ThyCa 成员邮件发放,样本可能不能代表全部 131I 治疗患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with 131I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to approximately 25,000 members of ThyCa: Thyroid Cancer Survivors' Association, Inc., and was available online from March to August 2018. Responses were included from adult patients regarding their most recent 131I therapy received between 2011 and 2018 ("after 2011"). Responses to this survey were compared with those of a similar previous survey for 131I therapies received between 1997 and 2009 ("before 2009"). Results: Of the 2,136 responses, 1,111 met the inclusion criteria. A similar percentage (∼98%) of patients were given oral or written radiation safety instructions (RSIs) after 2011 and before 2009, with a shift away from nuclear medicine physicians providing instructions after 2011 (43%) in comparison with before 2009 (54%; P < 0.001). More patients were able to discuss and individualize the RSIs after 2011 (67%) than before 2009 (29%; P < 0.001). However, 2% of patients do not recall ever receiving RSIs after 2011. After 2011, more patients were treated as outpatients (87%) than before 2009 (66%; P < 0.001). For outpatients, more patients were discharged within 30 min after receiving 131I therapy after 2011 (78%) than before 2009 (72%; P = 0.002). The same percentage (0.6%) of patients traveled more than 2 h with at least 2 occupants in the vehicle within approximately 1 m of the patient after 2011 and before 2009. Immediately after therapy, a similar percentage of patients stayed in a nonprivate residence after 2011 (4%) and before 2009 (5%; P = 0.28). Of the 27 outpatients released within 30 min to nonprivate residences, 2 patients received 5.55-11.1 GBq (150-299 mCi) of 131I. Conclusion: This survey suggests that since publication of the Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 on patient release after radioiodine therapy, there have been improvements in some radiation safety practices on release of outpatients, as well as improvements in patient compliance on travel and lodging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wu D, Gomes Lima CJ, Bloom G, et al. Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer. J Nucl Med. 2019. PMID: 31451488. doi:10.2967/jnumed.119.230730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。